Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107626 · ClinicalTrials.gov registry record · Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
A Phase 3 study of Lung Cancer, sponsored by ECOG-ACRIN Cancer Research Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,516
- Enrollment target
- 20
- Study locations
NCT01107626 is a Phase 3 study of Lung Cancer that has completed, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1,516 participants, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (63% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT01107626, a Phase 3 study of Lung Cancer, has completed, sponsored by ECOG-ACRIN Cancer Research Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,516 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Pemetrexed disodium may stop the growth of tumor cells by blocking some enzymes needed for cell growth. It is not yet known whether giving bevacizumab or pemetrexed disodium alone or in combination is more effective in treating non-squamous non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying bevacizumab and pemetrexed disodium alone or in combination after induction therapy to see how well they work in treating patients with advanced non-squamous non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
- DRUG Pemetrexed Disodium Heptahydrate
Study Locations (20)
California
- North Bay Cancer Center - Fairfield
- Todd Cancer Institute at Long Beach Memorial Medical Center - Long Beach
- Community Hospital of the Monterey Peninsula Comprehensive Cancer Center - Monterey
- Veterans Affairs Medical Center - Palo Alto - Palo Alto
- Feather River Hospital Cancer Center - Paradise
- Sutter Cancer Center at Roseville Medical Center - Roseville
- Sutter Cancer Center - Sacramento
- Salinas Valley Memorial Hospital - Salinas
- Stanford Cancer Center - Stanford
Colorado
- Aurora Presbyterian Hospital - Aurora
- Boulder Community Hospital - Boulder
- Penrose Cancer Center at Penrose Hospital - Colorado Springs
- St. Anthony Central Hospital - Denver
- Kaiser Permanente - Denver - Denver
- Porter Adventist Hospital - Denver
- Presbyterian - St. Luke's Medical Center - Denver
- St. Joseph Hospital - Denver
- Rose Medical Center - Denver
Alabama
- Regional Medical Center - Anniston
Alaska
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,516 participants |
| Start Date | 2010-10-25 |
| Est. Completion | 2021-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01107626
The ClinicalTrials.gov registry entry for NCT01107626 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,516 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 932-participant average among 409 other Lung Cancer trials with a reported enrollment target (63% higher). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT01107626 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT01107626 about?
NCT01107626 is a clinical study titled "Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the abi...
What is the current status of trial NCT01107626?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,516 participants. The study started on 2010-10-25. Estimated completion is 2021-08-17.
What conditions does trial NCT01107626 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT01107626?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Pemetrexed Disodium Heptahydrate (DRUG).
Who is sponsoring clinical trial NCT01107626?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01107626 being conducted?
This trial has 20 study locations across Alabama, Alaska, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.